Clinical Trials in Italy — Country Dashboard | 3,689 EU Studies

Filter these 3,689 trials by condition, phase, sponsor and more.

Open in Search →

3,689 Registered trials

1,496 Recruiting

1,844 Completed trials

891 Sponsors active

776 Research sites

Phase III

Phase II

Phase III: 1647 Phase II/III: 155 Phase II: 1116 Phase I/II: 212 Phase III/IV: 28 Phase IV: 153 Phase I: 119 Phase I (Other): 111 Phase I (FiH): 142 Other: 5 Other: 1

Oversight events in trials active here:

107 serious breaches 827 temporary halts 64 urgent safety measures 84 unexpected events 162 corrective measures across 455 trials

View oversight register →

Top conditions

Non-small cell lung cancer 135 Non-small cell lung cancer metastatic 50 Ovarian cancer 32 Diffuse large B-cell lymphoma 27 Breast cancer 27 Crohn's disease 26 Colorectal cancer 26 Endometrial cancer 25 Prostate cancer metastatic 23 Systemic lupus erythematosus 22 Myasthenia gravis 21 Asthma 20

Top sponsors

Merck Sharp & Dohme LLC 180 AstraZeneca AB 160 Novartis Pharma AG 145 F. Hoffmann-La Roche AG 138 Janssen - Cilag International 93 AbbVie Deutschland GmbH & Co. KG 89 Sanofi-Aventis Recherche & Developpement 76 Bristol-Myers Squibb Services Unlimited Company 65 Pfizer Inc. 64 Amgen Inc. 60 Glaxosmithkline Research & Development Limited 60 Boehringer Ingelheim International GmbH 50

Cities with most trials

All 250 cities →

All trials — page 52

3,689 total

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Recruiting

2023-504904-26-00 Phase III Progressive Pulmonary Fibrosis United Therapeutics Corp.
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease. Recruiting

2024-512633-32-00 Phase II Crohn's disease Sanofi-Aventis Recherche & Developpement
A multicenter, single-arm, open-label study to evaluate efficacy and safety of switching from anti-C5 antibody treatment to iptacopan treatm… Recruiting

2023-504550-35-00 Phase III Atypical Hemolytic Uremic Syndrome (aHUS) Novartis Pharma AG
Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste… Recruiting

2023-508507-20-00 Phase III Locally advanced or metastatic conventional chondrosarcoma w… Institut De Recherches Internationales Servier IRIS
A study in newly diagnosed glioblastoma patients that aims at testing the efficacy of Optune (Tumor Treating Fields), together with temozolo… Recruiting

2024-513550-30-00 Phase III Newly diagnosed Glioblastoma Novocure GmbH
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis Recruiting

2024-514845-12-00 Phase II Non-Cystic Fibrosis Bronchiectasis Verona Pharma PLC
CHAPTER-4 – A long term trial of deucrictibant treatment in prophylaxis against HAE attacks in adults and adolescents Recruiting

2024-516248-24-00 Phase III Hereditary Angioedema Pharvaris Netherlands B.V.
Gemcitabine plus nab-PAclitaxel as switch maiNTEnance versus cONtinuation of modified FOLFIRINOX as first-line chemotherapy in patients with… Recruiting

2024-515214-41-00 Phase III advanced pancreatic cancer Fondazione GONO G.I.
A study to investigate changes in symptoms in adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with … Recruiting

2024-513862-20-00 Phase III Chronic Rhinosinusitis with Nasal Polyposis AstraZeneca AB
Evaluation of the effect of statins, drugs in use to lower cholesterol, in reducing or delaying the progression of Arrhythmogenic Cardiomyop… Recruiting

2024-514643-28-00 Phase II Arrhythmogenic Cardiomyopathy (ACM) Centro Cardiologico Monzino S.p.A.
Ziftomenib in combination with chemotherapy for children with relapsed/refractory acute leukemia Recruiting

2023-505262-28-00 Phase I (Other) Acute Myeloid Leukemia Prinses Maxima Centrum voor Kinderoncologie B.V.
Metal Panel Patch Test Recruiting

2023-507972-35-01 Phase III Allergic contact dermatitis Smarthealth Inc.
PRESERVE-003: ONC-392 (Study Drug) Versus Docetaxel (Standard of Care) in Metastatic Non-small Cell Lung Cancer That Progressed on PD-1/PD-L… Recruiting

2023-505311-20-01 Phase III Metastatic Non-Small Cell Lung Cancer Oncoc4 Inc.
A Phase 3 Efficacy and Safety Study of Pitolisant in Patients with Prader-Willi Syndrome Recruiting

2023-508307-21-00 Phase III Prader-Willi syndrome Harmony Biosciences LLC
A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting

2024-515566-13-00 Phase III Diffuse Large B-Cell Lymphoma (DLBCL) Merck Sharp & Dohme LLC
EArly adminiStration of Ivabradine in CHILDren with heart failure Recruiting

2025-520916-32-00 Phase II Acute hearth failure in dilated cardiomyopathy Ospedale Pediatrico Bambino Gesu
A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi… Recruiting

2023-509070-36-00 Phase III Major Depressive Disorder with Insomnia Symptoms Janssen Cilag International
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Recruiting

2024-513285-19-00 Phase I Pancreatic Ductal Adeno Carcinoma Kura Oncology Inc.
A no-profit, open-label, phase II pilot study on the efficacy and safety of Alpelisib in patients with Dent 2 disease (ALPEDENT study) Recruiting

2024-514196-17-00 Phase II Dent 2 disease Ospedale Pediatrico Bambino Gesu
An open-label extension study with dazukibart for participants with idiopathic inflammatory myopathies (including DM or PM) who have complet… Recruiting

2024-514648-10-00 Phase III Idiopathic Inflammatory Myopathy (including dermatomyositis … Pfizer Inc.
A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED) Recruiting

2024-515252-20-00 Phase I/II Myelofibrosis (MF) unresponsive to JAK inhibitors iOnctura SA
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Recruiting

2024-513547-82-00 Phase III Transthyretin Amyloidosis Eidos Therapeutics Inc.
A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of adult patients with Short Bowel … Recruiting

2024-511994-31-00 Phase II Short Bowel Syndrome and Intestinal Failure (SBS-IF) without… Napo Therapeutics S.p.A.
Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting

2024-513443-93-00 Phase II Recurrent Meningioma without local treatment options (Surger… Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…

Showing 1,225–1,248 of 3,689 trials

← All countries